Breast Cancer Clinical Trial

Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer

Summary

The purpose of this study is to determine the safety profile, maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of single agent ISB1302 in subjects with HER2-positive metastatic breast cancer who have been treated with all known therapies known to confer clinical benefit.

View Full Description

Full Description

To determine the safety profile, maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of single agent ISB 1302 in subjects with HER2-positive metastatic breast cancer who have been treated with all known therapies known to confer clinical benefit.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Females with HER2-positive [IHC 2 +, with FISH confirmation] or 3+ [IHC or FISH] metastatic breast cancer that has progressed on last therapy. No more than 4 lines of therapy in metastatic setting (of which no more than 2 lines should be anti-HER2 antibody-based therapy).
Measurable disease, defined as per RECIST v1.1.
Eastern Cooperative Oncology Group (ECOG ) performance-status score of 2 or less
Adequate bone marrow, renal, and liver function.
Recovered from any previous surgery and no history of major surgery within the last 28 days prior to start of study drug
Must be willing to undergo pre-treatment and on-treatment biopsies in Part 1 and Part 2.

Exclusion Criteria:

Any suspected or proven immunocompromised state, or infections, such as history of positive human immunodeficiency virus (HIV), known active or chronic hepatitis B virus (HBV) or hepatitis C virus (HCV).
Any history or evidence of clinically significant cardiovascular disease.
Evidence of clinically significant cardiovascular and respiratory conditions
Previous antineoplastic treatment with immune checkpoint regulator or comparable immunotherapy within 8 weeks of starting study drug.
Chemotherapy, radiotherapy, molecular-targeted therapy, or biological therapies (including HER2-directed therapies) within 4 weeks of starting study drug
Hormone therapy within 2 weeks of starting study medications.
Diagnosed with another malignancy that requires active therapy
Brain metastases that require directed therapy.
Has not recovered from any therapy related toxicities from previous treatments.
Use of any investigational drug within 4 weeks from the start of study drug.
Any condition that, in the opinion of the Investigator, would interfere with evaluation of the study drug or interpretation of subject safety or study results.

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

1

Study ID:

NCT03983395

Recruitment Status:

Terminated

Sponsor:

Ichnos Sciences SA

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 5 Locations for this study

See Locations Near You

Ichnos Investigational Site 1
Gilbert Arizona, 85234, United States
Ichnos Investigational Site 5
Los Angeles California, 90048, United States
Ichnos Investigational Site 4
Louisville Kentucky, 40212, United States
Ichnos Investigational Site 2
Detroit Michigan, 48201, United States
Ichnos Investigational Site 3
Philadelphia Pennsylvania, 19107, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

1

Study ID:

NCT03983395

Recruitment Status:

Terminated

Sponsor:


Ichnos Sciences SA

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider